1 2012 88 EPIGENETIC BASIS OF OPIATE SUPPRESSION OF BDNF GENE EXPRESSION IN THE VENTRAL TEGMENTAL AREA. BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) HAS A CRUCIAL ROLE IN MODULATING NEURAL AND BEHAVIORAL PLASTICITY TO DRUGS OF ABUSE. WE FOUND A PERSISTENT DOWNREGULATION OF EXON-SPECIFIC BDNF EXPRESSION IN THE VENTRAL TEGMENTAL AREA (VTA) IN RESPONSE TO CHRONIC OPIATE EXPOSURE, WHICH WAS MEDIATED BY SPECIFIC EPIGENETIC MODIFICATIONS AT THE CORRESPONDING BDNF GENE PROMOTERS. EXPOSURE TO CHRONIC MORPHINE INCREASED STALLING OF RNA POLYMERASE II AT THESE BDNF PROMOTERS IN VTA AND ALTERED PERMISSIVE AND REPRESSIVE HISTONE MODIFICATIONS AND OCCUPANCY OF THEIR REGULATORY PROTEINS AT THE SPECIFIC PROMOTERS. FURTHERMORE, WE FOUND THAT MORPHINE SUPPRESSED BINDING OF PHOSPHO-CREB (CAMP RESPONSE ELEMENT BINDING PROTEIN) TO BDNF PROMOTERS IN VTA, WHICH RESULTED FROM ENRICHMENT OF TRIMETHYLATED H3K27 AT THE PROMOTERS, AND THAT DECREASED NURR1 (NUCLEAR RECEPTOR RELATED-1) EXPRESSION ALSO CONTRIBUTED TO BDNF REPRESSION AND ASSOCIATED BEHAVIORAL PLASTICITY TO MORPHINE. OUR FINDINGS SUGGEST PREVIOUSLY UNKNOWN EPIGENETIC MECHANISMS OF MORPHINE-INDUCED MOLECULAR AND BEHAVIORAL NEUROADAPTATIONS. 2015 2 4846 25 OPIATE ADDICTION AND COCAINE ADDICTION: UNDERLYING MOLECULAR NEUROBIOLOGY AND GENETICS. ADDICTIVE DISEASES, INCLUDING ADDICTION TO HEROIN, PRESCRIPTION OPIOIDS, OR COCAINE, POSE MASSIVE PERSONAL AND PUBLIC HEALTH COSTS. ADDICTIONS ARE CHRONIC RELAPSING DISEASES OF THE BRAIN CAUSED BY DRUG-INDUCED DIRECT EFFECTS AND PERSISTING NEUROADAPTATIONS AT THE EPIGENETIC, MRNA, NEUROPEPTIDE, NEUROTRANSMITTER, OR PROTEIN LEVELS. THESE NEUROADAPTATIONS, WHICH CAN BE SPECIFIC TO DRUG TYPE, AND THEIR RESULTANT BEHAVIORS ARE MODIFIED BY VARIOUS INTERNAL AND EXTERNAL ENVIRONMENTAL FACTORS, INCLUDING STRESS RESPONSIVITY, ADDICT MINDSET, AND SOCIAL SETTING. SPECIFIC GENE VARIANTS, INCLUDING VARIANTS ENCODING PHARMACOLOGICAL TARGET PROTEINS OR GENES MEDIATING NEUROADAPTATIONS, ALSO MODIFY VULNERABILITY AT PARTICULAR STAGES OF ADDICTION. GREATER UNDERSTANDING OF THESE INTERACTING FACTORS THROUGH LABORATORY-BASED AND TRANSLATIONAL STUDIES HAVE THE POTENTIAL TO OPTIMIZE EARLY INTERVENTIONS FOR THE THERAPY OF CHRONIC ADDICTIVE DISEASES AND TO REDUCE THE BURDEN OF RELAPSE. HERE, WE REVIEW THE MOLECULAR NEUROBIOLOGY AND GENETICS OF OPIATE ADDICTION, INCLUDING HEROIN AND PRESCRIPTION OPIOIDS, AND COCAINE ADDICTION. 2012 3 4498 35 MORPHINE REGULATES ARGONAUTE 2 AND TH EXPRESSION AND ACTIVITY BUT NOT MIR-133B IN MIDBRAIN DOPAMINERGIC NEURONS. EPIGENETIC CHANGES SUCH AS MICRORNAS (MIRS)/AGO2-INDUCED GENE SILENCING REPRESENT COMPLEX MOLECULAR SIGNATURE THAT REGULATE CELLULAR PLASTICITY. RECENT STUDIES SHOWED INVOLVEMENT OF MIRS AND AGO2 IN DRUG ADDICTION. IN THIS STUDY, WE SHOW THAT CHANGES IN GENE EXPRESSION INDUCED BY MORPHINE AND MORPHINE WITHDRAWAL OCCUR WITH CONCOMITANT EPIGENETIC MODIFICATIONS IN THE MESOLIMBIC DOPAMINERGIC (DA) PATHWAY [VENTRAL TEGMENTAL AREA (VTA)/NUCLEUS ACCUMBENS (NAC) SHELL], WHICH IS CRITICALLY INVOLVED IN DRUG-INDUCED DEPENDENCE. WE FOUND THAT ACUTE OR CHRONIC MORPHINE ADMINISTRATION AS WELL AS MORPHINE WITHDRAWAL DID NOT MODIFY MIR-133B MESSENGER RNA (MRNA) EXPRESSION IN THE VTA, WHEREAS AGO2 PROTEIN LEVELS WERE DECREASED AND INCREASED IN MORPHINE-DEPENDENT RATS AND AFTER MORPHINE WITHDRAWAL, RESPECTIVELY. THESE CHANGES WERE PARALLELED WITH ENHANCED AND DECREASED NAC TYROSINE HYDROXYLASE (TH) PROTEIN (AN EARLY DA MARKER) IN MORPHINE-DEPENDENT RATS AND AFTER WITHDRAWAL, RESPECTIVELY. WE ALSO OBSERVED CHANGES IN TH MRNA EXPRESSION IN THE VTA THAT COULD BE RELATED TO AGO2-INDUCED TRANSLATIONAL REPRESSION OF TH MRNA DURING MORPHINE WITHDRAWAL. HOWEVER, THE VTA NUMBER OF TH-POSITIVE NEURONS SUFFERED NO ALTERATIONS AFTER THE DIFFERENT TREATMENT. ACUTE MORPHINE ADMINISTRATION PRODUCED A MARKED INCREASE IN TH ACTIVITY AND DA TURNOVER IN THE NAC (SHELL). IN CONTRAST, PRECIPITATED MORPHINE WITHDRAWAL DECREASED TH ACTIVATION AND DID NOT CHANGE DA TURNOVER. THESE FINDINGS PROVIDE NEW INFORMATION INTO THE POSSIBLE CORRELATION BETWEEN AGO2/MIRS COMPLEX REGULATION AND DA NEURONS PLASTICITY DURING OPIATE ADDICTION. 2015 4 5035 23 PHARMACOEPIGENOMICS OF OPIATES AND METHADONE MAINTENANCE TREATMENT: CURRENT DATA AND PERSPECTIVES. CURRENT TREATMENTS OF OPIOID ADDICTION INCLUDE PRIMARILY MAINTENANCE MEDICATIONS SUCH AS METHADONE. CHRONIC EXPOSURE TO OPIATE AND/OR LONG-LASTING MAINTENANCE TREATMENT INDUCE MODULATIONS OF GENE EXPRESSION IN BRAIN AND PERIPHERAL TISSUES. THERE IS INCREASING EVIDENCE THAT EPIGENETIC MODIFICATIONS UNDERLIE THESE MODULATIONS. THIS REVIEW SUMMARIZES PUBLISHED RESULTS ON OPIOID-INDUCED EPIGENETIC CHANGES IN ANIMAL MODELS AND IN PATIENTS. THE EPIGENETIC MODIFICATIONS OBSERVED WITH OTHER DRUGS OF ABUSE OFTEN USED BY OPIATE ABUSERS ARE ALSO OUTLINED. SPECIFIC METHADONE MAINTENANCE TREATMENT INDUCED EPIGENETIC MODIFICATIONS AT DIFFERENT TREATMENT STAGES MAY BE COMBINED WITH THE ONES RESULTING FROM PATIENTS' SUBSTANCE USE HISTORY. THEREFORE, RESEARCH COMPARING GROUPS OF ADDICTS WITH SIMILAR HISTORY AND SUBSTANCES USE DISORDERS BUT CONTRASTING FOR WELL-CHARACTERIZED TREATMENT PHENOTYPES SHOULD BE ENCOURAGED. 2017 5 4500 31 MORPHINE-WITHDRAWAL AVERSIVE MEMORIES AND THEIR EXTINCTION MODULATE H4K5 ACETYLATION AND BRD4 ACTIVATION IN THE RAT HIPPOCAMPUS AND BASOLATERAL AMYGDALA. CHROMATIN MODIFICATION IS A CRUCIAL MECHANISM IN SEVERAL IMPORTANT PHENOMENA IN THE BRAIN, INCLUDING DRUG ADDICTION. PERSISTENCE OF DRUG CRAVING AND RISK OF RELAPSE COULD BE ATTRIBUTED TO DRUG-INDUCED EPIGENETIC MECHANISMS THAT SEEM TO BE CANDIDATES EXPLAINING LONG-LASTING DRUG-INDUCED BEHAVIOUR AND MOLECULAR ALTERATIONS. HISTONE ACETYLATION HAS BEEN PROPOSED TO REGULATE DRUG-SEEKING BEHAVIOURS AND THE EXTINCTION OF REWARDING MEMORY OF DRUG TAKING. IN THIS WORK, WE STUDIED THE EPIGENETIC REGULATION DURING CONDITIONED PLACE AVERSION AND AFTER EXTINCTION OF AVERSIVE MEMORY OF OPIATE WITHDRAWAL. THROUGH IMMUNOFLUORESCENCE ASSAYS, WE ASSESSED SOME EPIGENETIC MARKS (H4K5AC AND P-BRD4) IN CRUCIAL AREAS RELATED TO MEMORY RETRIEVAL -BASOLATERAL AMYGDALA (BLA) AND HIPPOCAMPUS-. ADDITIONALLY, TO TEST THE DEGREE OF TRANSCRIPTIONAL ACTIVATION, WE EVALUATED THE IMMEDIATE EARLY GENES (IEGS) RESPONSE (ARC, BDNF, CREB, EGR-1, FOS AND NFKB) AND SMARCC1 (CHROMATIN REMODELER) THROUGH RT-QPCR IN THESE NUCLEI. OUR RESULTS SHOWED INCREASED P-BRD4 AND H4K5AC LEVELS DURING AVERSIVE MEMORY RETRIEVAL, SUGGESTING A MORE OPEN CHROMATIN STATE. HOWEVER, TRANSCRIPTIONAL ACTIVATION OF THESE IEGS WAS NOT FOUND, THEREFORE SUGGESTING THAT OTHER SECONDARY RESPONSE MAY ALREADY BE HAPPENING. ADDITIONALLY, SMARCC1 LEVELS WERE REDUCED DUE TO MORPHINE CHRONIC ADMINISTRATION IN BLA AND DENTATE GYRUS. THE ACTIVATION MARKERS RETURNED TO CONTROL LEVELS AFTER THE RETRIEVAL OF AVERSIVE MEMORIES, REVEALING A MORE REPRESSED CHROMATIN STATE. TAKEN TOGETHER, OUR RESULTS SHOW A MAJOR ROLE OF THE TANDEM H4K5AC/P-BRD4 DURING THE RETRIEVAL OF AVERSIVE MEMORIES. THESE RESULTS MIGHT BE USEFUL TO ELUCIDATE NEW MOLECULAR TARGETS TO IMPROVE AND DEVELOP PHARMACOLOGICAL TREATMENTS TO ADDRESS ADDICTION AND TO AVOID DRUG RELAPSE. 2023 6 2580 26 EPIGENETICS OF MICRO-OPIOID RECEPTORS: INTERSECTION WITH HIV-1 INFECTION OF THE CENTRAL NERVOUS SYSTEM. THE ABUSE OF INTRAVENOUS DRUGS, SUCH AS HEROIN, HAS BECOME A MAJOR PUBLIC HEALTH CONCERN DUE TO THE INCREASED RISK OF HIV-1 INFECTION. OPIOIDS SUCH AS HEROIN WERE ORIGINALLY IDENTIFIED AND SUBSEQUENTLY ABUSED FOR THEIR ANALGESIC EFFECTS. HOWEVER, MANY INVESTIGATIONS HAVE FOUND ADDITIONAL EFFECTS OF OPIOIDS, INCLUDING REGULATION OF THE IMMUNE SYSTEM. AS SUCH, CHRONIC OPIOID ABUSE HAS BEEN SHOWN TO PROMOTE HIV-1 PATHOGENESIS AND FACILITATE HIV-1-ASSOCIATED NEUROCOGNITIVE DYSFUNCTION. CLINICAL OPIOIDS, SUCH AS MORPHINE AND METHADONE, AS WELL AS ILLICIT OPIOIDS, SUCH AS HEROIN, EXERT THEIR EFFECTS PRIMARILY THROUGH INTERACTIONS WITH THE MICRO-OPIOID RECEPTOR (MOR). HOWEVER, THE MECHANISMS BY WHICH OPIOIDS ENHANCE NEUROCOGNITIVE DYSFUNCTION THROUGH MOR-MEDIATED SIGNALING PATHWAYS ARE NOT COMPLETELY UNDERSTOOD. NEW FINDINGS IN THE REGULATION OF MOR EXPRESSION, PARTICULARLY EPIGENETIC AND TRANSCRIPTIONAL REGULATION AS WELL AS ALTERNATIVE SPLICING, SHEDS NEW INSIGHTS INTO POSSIBLE MECHANISMS OF HIV-1 AND OPIATE SYNERGY. IN THIS REVIEW, WE IDENTIFY MECHANISMS REGULATING MOR EXPRESSION AND PROPOSE NOVEL MECHANISMS BY WHICH OPIOIDS AND HIV-1 MAY MODULATE THIS REGULATION. ADDITIONALLY, WE SUGGEST THAT DIFFERENTIAL REGULATION OF NEWLY IDENTIFIED MOR ISOFORMS BY OPIOIDS AND HIV-1 HAS FUNCTIONAL CONSEQUENCE IN ENHANCING HIV-1 NEUROCOGNITIVE DYSFUNCTION. 2012 7 6602 24 TWO KINDS OF TRANSCRIPTION FACTORS MEDIATE CHRONIC MORPHINE-INDUCED DECREASE IN MIR-105 IN MEDIAL PREFRONTAL CORTEX OF RATS. CHRONIC MORPHINE ADMINISTRATION ALTERS GENE EXPRESSION IN DIFFERENT BRAIN REGIONS, AN EFFECT WHICH MAY CONTRIBUTE TO PLASTIC CHANGES ASSOCIATED WITH ADDICTIVE BEHAVIOR. THIS CHANGE IN GENE EXPRESSION IS MOST POSSIBLY MEDIATED BY ADDICTIVE DRUG-INDUCED EPIGENETIC REMODELING OF GENE EXPRESSION PROGRAMS. OUR PREVIOUS STUDIES SHOWED THAT CHRONIC MORPHINE-INDUCED DECREASE OF MIR-105 IN THE MEDIAL PREFRONTAL CORTEX (MPFC) CONTRIBUTED TO CONTEXT-INDUCED RETRIEVAL OF MORPHINE WITHDRAWAL MEMORY. HOWEVER, HOW CHRONIC MORPHINE TREATMENT DECREASES MIR-105 IN THE MPFC STILL REMAINS UNKNOWN. THE PRESENT STUDY SHOWS THAT CHRONIC MORPHINE INDUCES ADDICTION-RELATED CHANGE IN MIR-105 IN THE MPFC VIA TWO KINDS OF TRANSCRIPTION FACTORS: THE FIRST TRANSCRIPTION FACTOR IS CREB ACTIVATED BY MU RECEPTORS-ERK-P90RSK SIGNALING PATHWAY AND THE SECOND TRANSCRIPTION FACTOR IS GLUCOCORTICOID RECEPTOR (GR), WHICH AS A NEGATIVE TRANSCRIPTION FACTOR, MEDIATES CHRONIC MORPHINE-INDUCED DECREASE IN MIR-105 IN THE MPFC OF RATS. 2022 8 1706 32 DYNORPHIN/KOP AND NOCICEPTIN/NOP GENE EXPRESSION AND EPIGENETIC CHANGES BY COCAINE IN RAT STRIATUM AND NUCLEUS ACCUMBENS. COCAINE INDUCES NEUROCHEMICAL CHANGES OF ENDOGENOUS PRODYNORPHIN-KAPPA OPIOID RECEPTOR (PDYN-KOP) AND PRONOCICEPTIN/ORPHANINFQ-NOCICEPTIN RECEPTOR (PN/OFQ-NOP) SYSTEMS. BOTH SYSTEMS PLAY AN IMPORTANT ROLE IN REWARDING MECHANISMS AND ADDICTIVE STIMULUS PROCESSING BY MODULATING DRUG-INDUCED DOPAMINERGIC ACTIVATION IN THE MESOCORTICO-LIMBIC BRAIN AREAS. THEY ARE ALSO INVOLVED IN REGULATING STRESS MECHANISMS RELATED TO ADDICTION. THE AIM OF THIS STUDY WAS TO INVESTIGATE POSSIBLE CHANGES OF GENE EXPRESSION OF THE DYNORPHINERGIC AND NOCICEPTINERGIC SYSTEM COMPONENTS IN THE NUCLEUS ACCUMBENS (NA) AND IN MEDIAL AND LATERAL CAUDATE PUTAMEN (MCPU AND LCPU, RESPECTIVELY) OF RATS, FOLLOWING CHRONIC SUBCUTANEOUS INFUSION OF COCAINE. IN ADDITION, THE EPIGENETIC HISTONE MODIFICATIONS H3K4ME3 AND H3K27ME3 (AN ACTIVATING AND A REPRESSIVE MARKER, RESPECTIVELY) AT THE PROMOTER LEVEL OF THE PDYN, KOP, PN/OFQ AND NOP GENES WERE INVESTIGATED. RESULTS SHOWED THAT COCAINE INDUCED PDYN GENE EXPRESSION UP-REGULATION IN THE NA AND LCPU, AND ITS DOWN-REGULATION IN THE MCPU, WHEREAS KOP MRNA LEVELS WERE UNCHANGED. MOREOVER, COCAINE EXPOSURE DECREASED PN/OFQ GENE EXPRESSION IN THE NA AND LCPU, WHILE NOP MRNA LEVELS APPEARED SIGNIFICANTLY INCREASED IN THE NA AND DECREASED IN THE LCPU. SPECIFIC CHANGES OF THE H3K4ME3 AND H3K27ME3 LEVELS WERE FOUND AT PDYN, PN/OFQ, AND NOP GENE PROMOTER, CONSISTENT WITH THE OBSERVED GENE EXPRESSION ALTERATIONS. THE PRESENT FINDINGS CONTRIBUTE TO BETTER DEFINE THE ROLE OF ENDOGENOUS PDYN-KOP AND PN/OFQ-NOP SYSTEMS IN NEUROPLASTICITY MECHANISMS FOLLOWING CHRONIC COCAINE TREATMENT. THE EPIGENETIC HISTONE MODIFICATIONS UNDERLYING THE GENE EXPRESSION CHANGES LIKELY MEDIATE THE EFFECTS OF COCAINE ON TRANSCRIPTIONAL REGULATION OF SPECIFIC GENE PROMOTERS THAT RESULT IN LONG-LASTING DRUG-INDUCED PLASTICITY. 2014 9 3008 24 GENETIC-EPIGENETIC INTERACTION MODULATES MU-OPIOID RECEPTOR REGULATION. GENETIC AND EPIGENETIC MECHANISMS PLAY IMPORTANT ROLES IN PROTEIN EXPRESSION, ALTHOUGH AT DIFFERENT LEVELS. GENETIC VARIATIONS CAN ALTER CPG SITES AND THUS INFLUENCE THE EPIGENETIC REGULATION OF MRNA EXPRESSION, PROVIDING AN INCREASINGLY RECOGNIZED MECHANISM OF FUNCTIONAL CONSEQUENCES OF GENETIC POLYMORPHISMS. ONE OF THOSE GENETIC EFFECTS IS THE ASSOCIATION OF REDUCED MU-OPIOID RECEPTOR EXPRESSION WITH THE FUNCTIONAL GENETIC VARIANT N40D (OPRM1 118A>G, RS1799971) THAT CAUSES AN AMINO ACID EXCHANGE IN THE EXTRACELLULAR TERMINAL OF THE MU-OPIOID RECEPTOR. WE REPORT THAT THE NUCLEOTIDE EXCHANGE AT GENE POSITION +118 INTRODUCES A NEW CPG-METHYLATION SITE INTO THE OPRM1 DNA AT POSITION +117. THIS LEADS TO AN ENHANCED METHYLATION OF THE OPRM1 DNA AT THIS SITE AND DOWNSTREAM. THIS EPIGENETIC MECHANISM IMPEDES MU-OPIOID RECEPTOR UPREGULATION IN BRAIN TISSUE OF CAUCASIAN CHRONIC OPIATE ADDICTS, ASSESSED POSTMORTEM. WHILE IN WILD-TYPE SUBJECTS, A REDUCED SIGNALLING EFFICIENCY ASSOCIATED WITH CHRONIC HEROIN EXPOSURE WAS COMPENSATED BY AN INCREASED RECEPTOR DENSITY, THIS UPREGULATION WAS ABSENT IN CARRIERS OF THE 118G RECEPTOR VARIANT DUE TO A DIMINISHED OPRM1 MRNA TRANSCRIPTION. THUS, THE OPRM1 118A>G SNP VARIANT NOT ONLY REDUCES MICRO-OPIOID RECEPTOR SIGNALLING EFFICIENCY, BUT, BY A GENETIC-EPIGENETIC INTERACTION, REDUCES OPIOID RECEPTOR EXPRESSION AND THEREFORE, DEPLETES THE OPIOID SYSTEM OF A COMPENSATORY REACTION TO CHRONIC EXPOSURE. THIS DEMONSTRATES THAT A CHANGE IN THE GENOTYPE CAN CAUSE A CHANGE IN THE EPIGENOTYPE WITH MAJOR FUNCTIONAL CONSEQUENCES. 2012 10 2841 27 FREQUENCY OF THE DOPAMINE RECEPTOR D3 (RS6280) VS. OPIOID RECEPTOR MICRO1 (RS1799971) POLYMORPHIC RISK ALLELES IN PATIENTS WITH OPIOID USE DISORDER: A PREPONDERANCE OF DOPAMINERGIC MECHANISMS? WHILE OPIOIDS ARE A POWERFUL CLASS OF DRUGS THAT INHIBIT TRANSMISSION OF PAIN SIGNALS, THEIR USE IS TARNISHED BY THE CURRENT EPIDEMIC OF OPIOID USE DISORDER (OUD) AND OVERDOSE DEATHS. NOTWITHSTANDING PUBLISHED REPORTS, THERE REMAIN GAPS IN OUR KNOWLEDGE OF OPIOID RECEPTOR MECHANISMS AND THEIR ROLE IN OPIOID SEEKING BEHAVIOR. THUS, NOVEL INSIGHTS INTO MOLECULAR, NEUROGENETIC AND NEUROPHARMACOLOGICAL BASES OF OUD ARE NEEDED. WE PROPOSE THAT AN ADDICTIVE ENDOPHENOTYPE MAY NOT BE ENTIRELY SPECIFIC TO THE DRUG OF CHOICE BUT RATHER MAY BE GENERALIZABLE TO ALTERED BRAIN REWARD CIRCUITS IMPACTING NET MESOCORTICOLIMBIC DOPAMINE RELEASE. WE SUGGEST THAT GENETIC OR EPIGENETIC ALTERATIONS ACROSS DOPAMINERGIC REWARD SYSTEMS LEAD TO UNCONTROLLABLE SELF-ADMINISTRATION OF OPIOIDS AND OTHER DRUGS. FOR INSTANCE, DIMINISHED AVAILABILITY VIA KNOCKOUT OF DOPAMINE D3 RECEPTOR (DRD3) INCREASES VULNERABILITY TO OPIOIDS. BUILDING UPON THIS CONCEPT VIA THE USE OF A SOPHISTICATED POLYMORPHIC RISK ANALYSIS IN A HUMAN COHORT OF CHRONIC OPIOID USERS, WE FOUND EVIDENCE FOR A HIGHER FREQUENCY OF POLYMORPHIC DRD3 RISK ALLELE (RS6280) THAN OPIOID RECEPTOR MICRO1 (RS1799971). IN CONCLUSION, WHILE OPIOIDERGIC MECHANISMS ARE INVOLVED IN OUD, DOPAMINE-RELATED RECEPTORS MAY HAVE PRIMARY INFLUENCE ON OPIOID-SEEKING BEHAVIOR IN AFRICAN AMERICANS. THESE FINDINGS SUGGEST OUD-TARGETED NOVEL AND IMPROVED NEUROPHARMACOLOGICAL THERAPIES MAY REQUIRE FOCUS ON DRD3-MEDIATED REGULATION OF DOPAMINERGIC HOMEOSTASIS. 2022 11 5201 33 PRENATAL MORPHINE EXPOSURE INCREASES GAMMA OSCILLATION AND THETA COHERENCE IN THE RAT REWARD SYSTEM. PREVIOUS STUDIES HAVE FOUND THAT PRENATAL MORPHINE (PNM) EXPOSURE LEADS TO BOTH INCREASED AND DECREASED RISK OF SUBSTANCE ABUSE IN OFFSPRING. UNDERSTANDING MORE ABOUT THE NEUROBIOLOGICAL CHANGES AFTER THE PNM EXPOSURE WOULD HELP TO UNDERSTAND MORE ABOUT THIS ISSUE. SIGNALING FROM DOPAMINE NEURONS OF THE VENTRAL TEGMENTAL AREA (VTA) IN THE MESOACCUMBAL AND MESOCORTICAL PATHWAYS PLAYS A VITAL ROLE IN DRUG DEPENDENCY. TO PROVIDE FURTHER KNOWLEDGE ABOUT THE EFFECTS OF PNM ON DRUG SEEKING BEHAVIOR AND THE DOPAMINE SYSTEM. WE RECORDED LOCAL FIELD POTENTIALS (LFP) SIMULTANEOUSLY IN THE VTA, NAC (NUCLEUS ACCUMBENS), BLA (BASOLATERAL AMYGDALA) AND MPFC (MEDIAL PREFRONTAL CORTEX) IN MALE ADULT RATS PRENATALLY TREATED WITH SALINE OR MORPHINE. MORPHINE (10 MG/KG) INDUCED CONDITIONED PLACE PREFERENCE (CPP) ESTABLISHMENT, EXTINCTION AND PRIMING WERE TESTED TO INVESTIGATE THE EFFECTS OF PNM ON ADDICTIVE-LIKE BEHAVIOR. IN ADDITION, THE EXPRESSION OF NUCLEAR HISTONE DEACETYLASES (HDAC4, HDAC5), WHICH PLAYS ESSENTIAL EPIGENETIC ROLES IN NEUROPLASTICITY AFTER DRUG USE WERE ALSO TESTED IN VTA AND NAC. THE RESULTS SHOWED THAT PNM DID NOT CHANGE THE ACQUISITION OF MORPHINE CPP IN MALE RATS, BUT IMPAIRED CPP EXTINCTION AND MORPHINE (5 MG/KG) - PRIMED REINSTATEMENT OF CPP AFTER EXTINCTION. PNM INCREASED THE LOW GAMMA (30-60 HZ) AND HIGH (60-90 HZ) GAMMA LFP POWERS IN NAC AND BLA. PNM ALSO LEADS TO INCREASED THETA (4-9 HZ) COHERENCE BETWEEN VTA AND NAC, AND INCREASED HDAC5 EXPRESSION IN VTA. AFTER CHRONIC MORPHINE ADMINISTRATION, COHERENCE BETWEEN VTA-NAC, MPFC-NAC AND MPFC-BLA INCREASED SIGNIFICANTLY IN PNS RATS, BUT NO CHANGES WERE FIND IN PNM RATS, INDICATING IMPAIRED PLASTICITY IN BRAIN CIRCUITS. ALL THESE RESULTS SUGGEST THAT PNM EXPOSURE INCREASED REWARD PROCESSING IN ADULT MALE RATS, BUT IMPAIRED MORPHINE CPP EXTINCTION AND REINSTATEMENT, WHICH RELATE TO DECREASES NETWORK PLASTICITY AND INCREASED HDAC5 EXPRESSION IN THE REWARD SYSTEM. 2022 12 2883 27 G9A INHIBITS CREB-TRIGGERED EXPRESSION OF MU OPIOID RECEPTOR IN PRIMARY SENSORY NEURONS FOLLOWING PERIPHERAL NERVE INJURY. NEUROPATHIC PAIN, A DISTRESSING AND DEBILITATING DISORDER, IS STILL POORLY MANAGED IN CLINIC. OPIOIDS, LIKE MORPHINE, REMAIN THE MAINSTAY OF PRESCRIBED MEDICATIONS IN THE TREATMENT OF THIS DISORDER, BUT THEIR ANALGESIC EFFECTS ARE HIGHLY UNSATISFACTORY IN PART DUE TO NERVE INJURY-INDUCED REDUCTION OF OPIOID RECEPTORS IN THE FIRST-ORDER SENSORY NEURONS OF DORSAL ROOT GANGLIA. G9A IS A REPRESSOR OF GENE EXPRESSION. WE FOUND THAT NERVE INJURY-INDUCED INCREASES IN G9A AND ITS CATALYZED REPRESSIVE MARKER H3K9M2 ARE RESPONSIBLE FOR EPIGENETIC SILENCING OF OPRM1, OPRK1, AND OPRD1 GENES IN THE INJURED DORSAL ROOT GANGLIA. BLOCKING THESE INCREASES RESCUED DORSAL ROOT GANGLIA OPRM1, OPRK1, AND OPRD1 GENE EXPRESSION AND MORPHINE OR LOPERAMIDE ANALGESIA AND PREVENTED THE DEVELOPMENT OF MORPHINE OR LOPERAMIDE-INDUCED ANALGESIC TOLERANCE UNDER NEUROPATHIC PAIN CONDITIONS. CONVERSELY, MIMICKING THESE INCREASES REDUCED THE EXPRESSION OF THREE OPIOID RECEPTORS AND PROMOTED THE MU OPIOID RECEPTOR-GATED RELEASE OF PRIMARY AFFERENT NEUROTRANSMITTERS. MECHANISTICALLY, NERVE INJURY-INDUCED INCREASES IN THE BINDING ACTIVITY OF G9A AND H3K9ME2 TO THE OPRM1 GENE WERE ASSOCIATED WITH THE REDUCED BINDING OF CYCLIC AMP RESPONSE ELEMENT BINDING PROTEIN TO THE OPRM1 GENE. THESE FINDINGS SUGGEST THAT G9A PARTICIPATES IN THE NERVE INJURY-INDUCED REDUCTION OF THE OPRM1 GENE LIKELY THROUGH G9A-TRIGGERED BLOCKAGE IN THE ACCESS OF CYCLIC AMP RESPONSE ELEMENT BINDING PROTEIN TO THIS GENE. 2016 13 5535 29 ROLE OF BRD4 PHOSPHORYLATION IN THE NUCLEUS ACCUMBENS IN RELAPSE TO COCAINE-SEEKING BEHAVIOR IN MICE. COCAINE ADDICTION IS A CHRONIC RELAPSING BRAIN DISORDER CHARACTERIZED BY COMPULSIVE DRUG SEEKING. PRELIMINARY STUDY SUGGESTED THAT BROMODOMAIN-CONTAINING PROTEIN 4 (BRD4), AN EPIGENETIC READER PROTEIN, PARTICIPATES IN COCAINE-INDUCED REWARD AND NEUROPLASTICITY. HOWEVER, THE EXACT ROLE OF BRD4 IN COCAINE ADDICTION, PARTICULARLY COCAINE RELAPSE, REMAINS ELUSIVE. IN THIS STUDY, WE FOUND THAT BRD4 PHOSPHORYLATION IN THE NUCLEUS ACCUMBENS (NAC) WAS CLOSELY RELATED TO THE MAINTENANCE OF COCAINE REINFORCEMENT AND RELAPSE IN DIFFERENT COCAINE EXPOSURE PARADIGMS. COCAINE SIGNIFICANTLY INCREASED THE BINDING OF PHOSPHORYLATED BRD4 (PBRD4) AT THE PROMOTER OF GRIA2 AND BDNF GENES IN THE NAC. (+)JQ1, A SELECTIVE BRD4 INHIBITOR, MARKEDLY REDUCED THE REINFORCEMENT AND REINSTATEMENT OF COCAINE-SEEKING BEHAVIORS, WHICH WAS ACCOMPANIED BY THE DECREASED EXPRESSIONS OF GRIA2 AND BDNF. FURTHERMORE, CHROMATIN IMMUNOPRECIPITATION ASSAY SHOWED THAT (+)JQ1 CLEARLY ATTENUATED COCAINE-ENHANCED BINDING OF PBRD4 AT THE PROMOTOR OF GRIA2 AND BDNF GENES. BLOCKADE OF CASEIN KINASE II SIGNIFICANTLY ATTENUATED BRD4 PHOSPHORYLATION AND COCAINE RELAPSE-LIKE BEHAVIORS, SUGGESTING THE IMPORTANT ROLE OF PBRD4 IN MODULATING COCAINE EFFECT. TOGETHER, OUR FINDINGS SUGGEST THAT BRD4 PHOSPHORYLATION IN THE NAC MODULATES MULTIPLE ADDICTION-RELATED BEHAVIORS OF COCAINE AND PARTICULARLY RELAPSE TO COCAINE-SEEKING BEHAVIORS. INHIBITION OF BRD4 ACTIVITY MAY BE A NOVEL TARGET AGAINST COCAINE ADDICTION AND RELAPSE. 2020 14 856 20 CHROMATIN ACCESSIBILITY MAPPING OF THE STRIATUM IDENTIFIES TYROSINE KINASE FYN AS A THERAPEUTIC TARGET FOR HEROIN USE DISORDER. THE CURRENT OPIOID EPIDEMIC NECESSITATES A BETTER UNDERSTANDING OF HUMAN ADDICTION NEUROBIOLOGY TO DEVELOP EFFICACIOUS TREATMENT APPROACHES. HERE, WE PERFORM GENOME-WIDE ASSESSMENT OF CHROMATIN ACCESSIBILITY OF THE HUMAN STRIATUM IN HEROIN USERS AND MATCHED CONTROLS. OUR STUDY REVEALS DISTINCT NEURONAL AND NON-NEURONAL EPIGENETIC SIGNATURES, AND IDENTIFIES A LOCUS IN THE PROXIMITY OF THE GENE ENCODING TYROSINE KINASE FYN AS THE MOST AFFECTED REGION IN NEURONS. FYN EXPRESSION, KINASE ACTIVITY AND THE PHOSPHORYLATION OF ITS TARGET TAU ARE INCREASED BY HEROIN USE IN THE POST-MORTEM HUMAN STRIATUM, AS WELL AS IN RATS TRAINED TO SELF-ADMINISTER HEROIN AND PRIMARY STRIATAL NEURONS TREATED WITH CHRONIC MORPHINE IN VITRO. PHARMACOLOGICAL OR GENETIC MANIPULATION OF FYN ACTIVITY SIGNIFICANTLY ATTENUATES HEROIN SELF-ADMINISTRATION AND RESPONDING FOR DRUG-PAIRED CUES IN RODENTS. OUR FINDINGS SUGGEST THAT STRIATAL FYN IS AN IMPORTANT DRIVER OF HEROIN-RELATED NEURODEGENERATIVE-LIKE PATHOLOGY AND DRUG-TAKING BEHAVIOR, MAKING FYN A PROMISING THERAPEUTIC TARGET FOR HEROIN USE DISORDER. 2020 15 5021 29 PERSISTENT PAIN MAINTAINS MORPHINE-SEEKING BEHAVIOR AFTER MORPHINE WITHDRAWAL THROUGH REDUCED MECP2 REPRESSION OF GLUA1 IN RAT CENTRAL AMYGDALA. AS LONG-TERM OPIOIDS ARE INCREASINGLY USED FOR CONTROL OF CHRONIC PAIN, HOW PAIN AFFECTS THE REWARDING EFFECT OF OPIOIDS AND HENCE RISK OF PRESCRIPTION OPIOID MISUSE AND ABUSE REMAINS A HEALTHCARE CONCERN AND A CHALLENGING ISSUE IN CURRENT PAIN MANAGEMENT. IN THIS STUDY, USING A RAT MODEL OF MORPHINE SELF-ADMINISTRATION, WE INVESTIGATED THE MOLECULAR MECHANISMS UNDERLYING THE IMPACT OF PAIN ON OPERANT BEHAVIOR OF MORPHINE INTAKE AND MORPHINE SEEKING BEFORE AND AFTER MORPHINE WITHDRAWAL. WE FOUND THAT RATS WITH PERSISTENT PAIN CONSUMED A SIMILAR AMOUNT OF DAILY MORPHINE TO THAT IN CONTROL RATS WITHOUT PAIN, BUT MAINTAINED THEIR LEVEL-PRESSING BEHAVIOR OF MORPHINE SEEKING AFTER ABSTINENCE OF MORPHINE AT 0.2 MG/KG, WHEREAS THIS BEHAVIOR WAS GRADUALLY DIMINISHED IN CONTROL RATS. IN THE CENTRAL NUCLEUS OF AMYGDALA (CEA), A LIMBIC STRUCTURE CRITICALLY INVOLVED IN THE AFFECTIVE DIMENSION OF PAIN, PROTEINS OF GLUA1 SUBUNITS OF GLUTAMATE AMPA RECEPTORS WERE UPREGULATED DURING MORPHINE WITHDRAWAL, AND VIRAL KNOCKDOWN OF CEA GLUA1 ELIMINATED THE MORPHINE-SEEKING BEHAVIOR IN WITHDRAWN RATS OF THE PAIN GROUP. CHROMATIN IMMUNOPRECIPITATION ANALYSIS REVEALED THAT THE METHYL CPG-BINDING PROTEIN 2 (MECP2) WAS ENRICHED IN THE PROMOTER REGION OF GRIA1 ENCODING GLUA1 AND THIS ENRICHMENT WAS SIGNIFICANTLY ATTENUATED IN WITHDRAWN RATS OF THE PAIN GROUP. FURTHERMORE, VIRAL OVEREXPRESSION OF CEA MECP2 REPRESSED THE GLUA1 LEVEL AND ELIMINATED THE MAINTENANCE OF MORPHINE-SEEKING BEHAVIOR AFTER MORPHINE WITHDRAWAL. THESE RESULTS SUGGEST DIRECT MECP2 REPRESSION OF GLUA1 FUNCTION AS A LIKELY MECHANISM FOR MORPHINE-SEEKING BEHAVIOR MAINTAINED BY LONG-LASTING AFFECTIVE PAIN AFTER MORPHINE WITHDRAWAL. 2015 16 4499 31 MORPHINE WITHDRAWAL PRODUCES ERK-DEPENDENT AND ERK-INDEPENDENT EPIGENETIC MARKS IN NEURONS OF THE NUCLEUS ACCUMBENS AND LATERAL SEPTUM. EPIGENETIC CHANGES SUCH AS COVALENT MODIFICATIONS OF HISTONE PROTEINS REPRESENT COMPLEX MOLECULAR SIGNATURES THAT PROVIDE A CELLULAR MEMORY OF PREVIOUSLY EXPERIENCED STIMULI WITHOUT IRREVERSIBLE CHANGES OF THE GENETIC CODE. IN THIS STUDY WE SHOW THAT NEW GENE EXPRESSION INDUCED IN VIVO BY MORPHINE WITHDRAWAL OCCURS WITH CONCOMITANT EPIGENETIC MODIFICATIONS IN BRAIN REGIONS CRITICALLY INVOLVED IN DRUG-DEPENDENT BEHAVIORS. WE FOUND THAT NALOXONE-PRECIPITATED WITHDRAWAL, BUT NOT CHRONIC MORPHINE ADMINISTRATION, CAUSED A STRONG INDUCTION OF PHOSPHO-HISTONE H3 IMMUNOREACTIVITY IN THE NUCLEUS ACCUMBENS (NAC) SHELL/CORE AND IN THE LATERAL SEPTUM (LS), A CHANGE THAT WAS ACCOMPANIED BY AUGMENTED H3 ACETYLATION (LYS14) IN NEURONS OF THE NAC SHELL. MORPHINE WITHDRAWAL INDUCED THE PHOSPHORYLATION OF THE EPIGENETIC FACTOR METHYL-CPG-BINDING PROTEIN 2 (MECP2) IN SER421 BOTH IN THE LS AND THE NAC SHELL. THESE EPIGENETIC CHANGES WERE ACCOMPANIED BY THE ACTIVATION OF MEMBERS OF THE ERK PATHWAY AS WELL AS INCREASED EXPRESSION OF THE IMMEDIATE EARLY GENES (IEG) C-FOS AND ACTIVITY-REGULATED CYTOSKELETON-ASSOCIATED PROTEIN (ARC/ARG3.1). USING A PHARMACOLOGICAL APPROACH, WE FOUND THAT H3 PHOSPHORYLATION AND IEG EXPRESSION WERE PARTIALLY DEPENDENT ON ERK ACTIVATION, WHILE MECP2 PHOSPHORYLATION WAS FULLY ERK-INDEPENDENT. THESE FINDINGS PROVIDE NEW IMPORTANT INFORMATION ON THE ROLE OF THE ERK PATHWAY IN THE REGULATION OF EPIGENETIC MARKS AND GENE EXPRESSION THAT MAY CONCUR TO REGULATE IN VIVO THE CELLULAR CHANGES UNDERLYING THE ONSET OF THE OPIOID WITHDRAWAL SYNDROME. 2013 17 2839 29 FOSB INDUCTION IN NUCLEUS ACCUMBENS BY COCAINE IS REGULATED BY E2F3A. THE TRANSCRIPTION FACTOR DELTAFOSB HAS BEEN PROPOSED AS A MOLECULAR SWITCH FOR THE TRANSITION FROM CASUAL, VOLITIONAL DRUG USE INTO A CHRONICALLY ADDICTED STATE, BUT THE UPSTREAM REGULATORY MECHANISMS GOVERNING DELTAFOSB EXPRESSION ARE INCOMPLETELY UNDERSTOOD. IN THIS STUDY, WE FIND A NOVEL REGULATORY ROLE FOR THE TRANSCRIPTION FACTOR E2F3, RECENTLY IMPLICATED IN TRANSCRIPTIONAL REGULATION BY COCAINE, IN CONTROLLING DELTAFOSB INDUCTION IN THE MOUSE NUCLEUS ACCUMBENS (NAC) FOLLOWING COCAINE ADMINISTRATION. WE FIND THAT AN E2F CONSENSUS SEQUENCE 500 BP UPSTREAM OF THE FOSB TRANSCRIPTION START SITE IS ENRICHED FOR E2F3 SPECIFICALLY OVER OTHER E2F ISOFORMS. WE FURTHER CONCLUDE THAT DELTAFOSB EXPRESSION IS REGULATED SPECIFICALLY BY E2F3A, NOT E2F3B, THAT E2F3A EXPRESSION IS SPECIFIC TO D1 RECEPTOR-EXPRESSING MEDIUM SPINY NEURONS, AND THAT E2F3A OVEREXPRESSION IN NAC RECAPITULATES THE INDUCTION OF FOSB AND DELTAFOSB MRNA EXPRESSION OBSERVED AFTER CHRONIC COCAINE EXPOSURE. E2F3A KNOCKDOWN IN NAC DOES NOT ABOLISH DELTAFOSB INDUCTION BY COCAINE, A RESULT CONSISTENT WITH PREVIOUSLY PUBLISHED DATA SHOWING THAT SINGULAR KNOCKDOWN OF UPSTREAM REGULATORS OF DELTAFOSB IS INSUFFICIENT TO BLOCK COCAINE-INDUCED EXPRESSION. FINALLY, TO ELUCIDATE POTENTIAL COMBINATORIAL EPIGENETIC MECHANISMS INVOLVED IN E2F3A'S REGULATION OF FOSB, WE EXPLORE H3K4ME3 ENRICHMENT AT THE FOSB PROMOTER AND FIND THAT IT IS NOT ENHANCED BY E2F3A OVEREXPRESSION, SUGGESTING THAT IT MAY INSTEAD BE A PRE-EXISTING PERMISSIVE MARK ALLOWING FOR E2F3A TO INTERACT WITH FOSB. TOGETHER, THESE FINDINGS SUPPORT A ROLE FOR E2F3A AS A NOVEL, UPSTREAM REGULATOR OF THE ADDICTION-MEDIATING TRANSCRIPTION FACTOR DELTAFOSB IN NAC. 2019 18 4418 16 MOLECULAR AND EPIGENETIC ASPECTS OF OPIOID RECEPTORS IN DRUG ADDICTION AND PAIN MANAGEMENT IN SPORT. OPIOIDS ARE SUBSTANCES DERIVED FROM OPIUM (NATURAL OPIOIDS). IN ITS RAW STATE, OPIUM IS A GUMMY LATEX EXTRACTED FROM PAPAVER SOMNIFERUM. THE USE OF OPIOIDS AND THEIR NEGATIVE HEALTH CONSEQUENCES AMONG PEOPLE WHO USE DRUGS HAVE BEEN STUDIED. TODAY, OPIOIDS ARE STILL THE MOST COMMONLY USED AND EFFECTIVE ANALGESIC TREATMENTS FOR SEVERE PAIN, BUT THEIR USE AND ABUSE CAUSES DETRIMENTAL SIDE EFFECTS FOR HEALTH, INCLUDING ADDICTION, THUS IMPACTING THE USER'S QUALITY OF LIFE AND CAUSING OVERDOSE. THE MESOCORTICOLIMBIC DOPAMINERGIC CIRCUITRY REPRESENTS THE BRAIN CIRCUIT MEDIATING BOTH NATURAL REWARDS AND THE REWARDING ASPECTS OF NEARLY ALL DRUGS OF ABUSE, INCLUDING OPIOIDS. HENCE, UNDERSTANDING HOW OPIOIDS AFFECT THE FUNCTION OF DOPAMINERGIC CIRCUITRY MAY BE USEFUL FOR BETTER KNOWLEDGE OF THE PROCESS AND TO DEVELOP EFFECTIVE THERAPEUTIC STRATEGIES IN ADDICTION. THE AIM OF THIS REVIEW WAS TO SUMMARIZE THE MAIN FEATURES OF OPIOIDS AND OPIOID RECEPTORS AND FOCUS ON THE MOLECULAR AND UPCOMING EPIGENETIC MECHANISMS LEADING TO OPIOID ADDICTION. SINCE SYNTHETIC OPIOIDS CAN BE EFFECTIVE FOR PAIN MANAGEMENT, THEIR ABILITY TO INDUCE ADDICTION IN ATHLETES, WITH THE RISK OF INCURRING DOPING, IS ALSO DISCUSSED. 2023 19 4878 31 OVEREXPRESSION OF THE HISTONE DIMETHYLTRANSFERASE G9A IN NUCLEUS ACCUMBENS SHELL INCREASES COCAINE SELF-ADMINISTRATION, STRESS-INDUCED REINSTATEMENT, AND ANXIETY. REPEATED EXPOSURE TO COCAINE INDUCES LASTING EPIGENETIC CHANGES IN NEURONS THAT PROMOTE THE DEVELOPMENT AND PERSISTENCE OF ADDICTION. ONE EPIGENETIC ALTERATION INVOLVES REDUCTIONS IN LEVELS OF THE HISTONE DIMETHYLTRANSFERASE G9A IN NUCLEUS ACCUMBENS (NAC) AFTER CHRONIC COCAINE ADMINISTRATION. THIS REDUCTION IN G9A MAY ENHANCE COCAINE REWARD BECAUSE OVEREXPRESSING G9A IN THE NAC DECREASES COCAINE-CONDITIONED PLACE PREFERENCE. THEREFORE, WE HYPOTHESIZED THAT HSV-MEDIATED G9A OVEREXPRESSION IN THE NAC SHELL (NACSH) WOULD ATTENUATE COCAINE SELF-ADMINISTRATION (SA) AND COCAINE-SEEKING BEHAVIOR. INSTEAD, WE FOUND THAT G9A OVEREXPRESSION, AND THE RESULTING INCREASE IN HISTONE 3 LYSINE 9 DIMETHYLATION (H3K9ME2), INCREASES SENSITIVITY TO COCAINE REINFORCEMENT AND ENHANCES MOTIVATION FOR COCAINE IN SELF-ADMINISTERING MALE RATS. MOREOVER, WHEN G9A OVEREXPRESSION IS LIMITED TO THE INITIAL 15 D OF COCAINE SA TRAINING, IT PRODUCES AN ENDURING POSTEXPRESSION ENHANCEMENT IN COCAINE SA AND PROLONGED (OVER 5 WEEKS) INCREASES IN REINSTATEMENT OF COCAINE SEEKING INDUCED BY FOOT-SHOCK STRESS, BUT IN THE ABSENCE OF CONTINUED GLOBAL ELEVATIONS IN H3K9ME2. THE INCREASE IN STRESS-INDUCED REINSTATEMENT IS PARALLELED BY HEIGHTENED ANXIETY MEASURES, SUGGESTING THAT COUNTERING THE COCAINE-INDUCED DECREASES IN ENDOGENOUS G9A WITH ECTOPIC G9A OVEREXPRESSION LEADS TO LASTING ANXIOGENIC EFFECTS. FINALLY, WE FOUND AN ENDURING REDUCTION IN PHOSPHORYLATED CAMP-RESPONSE ELEMENT BINDING PROTEIN LEVELS IN THE NACSH THAT COULD ACCOUNT FOR THE INCREASED ANXIETY. THESE DATA DEMONSTRATE A NOVEL ROLE FOR G9A IN PROMOTING COMORBID COCAINE ADDICTION AND ANXIETY AND SUGGEST THAT INCREASED EPIGENETIC REPRESSION OF TRANSCRIPTION THROUGH H3K9 DURING COCAINE USE CAN HAVE LONG-LASTING AND UNEXPECTED NEGATIVE CONSEQUENCES ON BEHAVIOR.SIGNIFICANCE STATEMENT COCAINE ADDICTION IS A NEUROPSYCHIATRIC DISORDER THAT IS DETRIMENTAL TO SOCIETY AND CURRENTLY HAS NO EFFECTIVE TREATMENTS. THE DIFFICULTY IN TREATING DRUG ADDICTION IS COMPOUNDED BY THE HIGH COMORBIDITY WITH OTHER PSYCHIATRIC ILLNESSES, INCLUDING ANXIETY DISORDERS. HERE, WE DEMONSTRATE THAT G9A, AN EPIGENETIC REPRESSOR OF GENE EXPRESSION, ACTING IN THE NUCLEUS ACCUMBENS, A BRAIN REWARD REGION, IS CAPABLE OF INCREASING BOTH ADDICTION- AND ANXIETY-LIKE BEHAVIORS IN RATS. THESE FINDINGS ARE INTRIGUING BECAUSE REPEATED COCAINE EXPOSURE DECREASES G9A IN THIS REGION AND THEREBY ENHANCES EXPRESSION OF CERTAIN ADDICTION-PROMOTING GENES. HOWEVER, OUR RESULTS SUGGEST THAT COUNTERING THIS COCAINE-INDUCED DECREASE IN G9A ACTIVITY ACTUALLY EXACERBATES ADDICTION AND SENSITIVITY TO RELAPSE UNDER STRESSFUL SITUATIONS. 2018 20 4163 30 MECP2 REPRESSION OF G9A IN REGULATION OF PAIN AND MORPHINE REWARD. OPIOIDS ARE COMMONLY USED FOR PAIN RELIEF, BUT THEIR STRONG REWARDING EFFECTS DRIVE OPIOID MISUSE AND ABUSE. HOW PAIN AFFECTS THE LIABILITY OF OPIOID ABUSE IS UNKNOWN AT PRESENT. IN THIS STUDY, WE IDENTIFIED AN EPIGENETIC REGULATING CASCADE ACTIVATED BY BOTH PAIN AND THE OPIOID MORPHINE. BOTH PERSISTENT PAIN AND REPEATED MORPHINE UPREGULATED THE TRANSCRIPTIONAL REGULATOR MECP2 IN MOUSE CENTRAL NUCLEUS OF THE AMYGDALA (CEA). CHROMATIN IMMUNOPRECIPITATION ANALYSIS REVEALED THAT MECP2 BOUND TO AND REPRESSED THE TRANSCRIPTIONAL REPRESSOR HISTONE DIMETHYLTRANSFERASE G9A, REDUCING G9A-CATALYZED REPRESSIVE MARK H3K9ME2 IN CEA. REPRESSION OF G9A ACTIVITY INCREASED EXPRESSION OF BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF). BEHAVIORALLY, PERSISTENT INFLAMMATORY PAIN INCREASED THE SENSITIVITY TO ACQUIRING MORPHINE-INDUCED, REWARD-RELATED BEHAVIOR OF CONDITIONED PLACE PREFERENCE IN MICE. LOCAL VIRAL VECTOR-MEDIATED MECP2 OVEREXPRESSION, CRE-INDUCED G9A KNOCKDOWN, AND CEA APPLICATION OF BDNF MIMICKED, WHEREAS MECP2 KNOCKDOWN INHIBITED, THE PAIN EFFECT. THESE RESULTS SUGGEST THAT MECP2 DIRECTLY REPRESSES G9A AS A SHARED MECHANISM IN CENTRAL AMYGDALA FOR REGULATION OF EMOTIONAL RESPONSES TO PAIN AND OPIOID REWARD, AND FOR THEIR BEHAVIORAL INTERACTION. 2014